Tobacco Companies Pour $1 Billion Into Nicotine Pouches as Sales Seen Topping $40 Billion by 2033
Updated
Updated · The New York Times · Jul 6
Tobacco Companies Pour $1 Billion Into Nicotine Pouches as Sales Seen Topping $40 Billion by 2033
3 articles · Updated · The New York Times · Jul 6
Summary
More than $1 billion is flowing into U.S. nicotine-pouch production as tobacco companies expand factories and add jobs from Florida to Colorado.
The push is driven by Zyn-fueled demand and cigarette declines, with global pouch sales projected to jump to more than $40 billion by 2033 from $6.9 billion in 2025.
States are helping finance that buildout with incentives, including $4.5 million in Colorado tax credits for Philip Morris International’s $600 million Aurora plant.
Public health experts say the boom revives Juul-era concerns, arguing companies are marketing addictive nicotine pouches, gums and lozenges as safer alternatives while increasing potency.
With tobacco giants investing billions, can regulators prevent this boom from becoming the next youth vaping crisis?
As nicotine pouch sales boom, are they a gateway for youth addiction or a viable off-ramp for adult smokers?
Are states trading future public health costs for short-term economic gains by subsidizing new nicotine pouch plants?
Nicotine Pouches in 2025-2026: Explosive Market Growth, Health Concerns, and the Policy Crossroads
Overview
The nicotine pouch market is rising rapidly, driven by a strong shift toward smoke-free alternatives. Tobacco companies, especially Philip Morris International (PMI), are racing to lead this trend in the U.S. by investing in products like ZYN, which has become the top smoke-free brand. PMI’s regulatory achievements, including a large share of FDA authorizations, support its strategy to speed up America’s move away from traditional tobacco. As ZYN’s sales grow and PMI expands production, the market’s momentum highlights how innovation, regulation, and changing consumer demand are shaping the future of nicotine products.